{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:01:19Z","timestamp":1787032879457,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,15]]},"DOI":"10.7759\/cureus.54268","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T21:56:11Z","timestamp":1708034171000},"source":"Crossref","is-referenced-by-count":16,"title":["A Comparison of the Effectiveness of Nintedanib and Pirfenidone in Treating Idiopathic Pulmonary Fibrosis: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Ruzhual K","family":"Man","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaresh","family":"Gogikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Nanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi Sai Niharika","family":"Janga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hembashima G","family":"Sambe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Yasir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivana","family":"Ramphall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"Lederer DJ","year":"2018","unstructured":"Lederer DJ, Martinez FJ.  Idiopathic pulmonary fibrosis. N Engl J Med. 2018, 378:1811-23. 10.1056\/NEJMra1705751","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00073012","article-title":"The pathogenesis of pulmonary fibrosis: a moving target","volume":"41","author":"Wuyts WA","year":"2013","unstructured":"Wuyts WA, Agostini C, Antoniou KM, et al.. The pathogenesis of pulmonary fibrosis: a moving target. Eur Respir J. 2013, 41:1207-18. 10.1183\/09031936.00073012","journal-title":"Eur Respir J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-021-01711-1","article-title":"Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management","volume":"22","author":"Luppi F","year":"2021","unstructured":"Luppi F, Kalluri M, Faverio P, Kreuter M, Ferrara G. Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management. Respir Res. 2021, 22:109. 10.1186\/s12931-021-01711-1","journal-title":"Respir Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201410-1876PP","article-title":"Blue journal conference. Aging and susceptibility to lung disease","volume":"191","author":"Thannickal VJ","year":"2015","unstructured":"Thannickal VJ, Murthy M, Balch WE, et al.. Blue journal conference. Aging and susceptibility to lung disease. Am J Respir Crit Care Med. 2015, 191:261-9. 10.1164\/rccm.201410-1876PP","journal-title":"Am J Respir Crit Care Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2009.081170","article-title":"Emerging concepts in the pathogenesis of lung fibrosis","volume":"175","author":"Hardie WD","year":"2009","unstructured":"Hardie WD, Glasser SW, Hagood JS. Emerging concepts in the pathogenesis of lung fibrosis. Am J Pathol. 2009, 175:3-16. 10.2353\/ajpath.2009.081170","journal-title":"Am J Pathol"},{"key":"ref6","article-title":"The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis","volume":"138","author":"Kuhn C","year":"1991","unstructured":"Kuhn C, McDonald JA. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol. 1991, 138:1257-65.","journal-title":"Am J Pathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-1093-z","article-title":"Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-\u03b21","volume":"20","author":"Jin J","year":"2019","unstructured":"Jin J, Togo S, Kadoya K, et al.. Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-\u03b21. Respir Res. 2019, 20:119. 10.1186\/s12931-019-1093-z","journal-title":"Respir Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00766-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of nintedanib","volume":"58","author":"Wind S","year":"2019","unstructured":"Wind S, Schmid U, Freiwald M, et al.. Clinical pharmacokinetics and pharmacodynamics of nintedanib. Clin Pharmacokinet. 2019, 58:1131-47. 10.1007\/s40262-019-00766-0","journal-title":"Clin Pharmacokinet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1338268","article-title":"The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"16","author":"Cottin V","year":"2017","unstructured":"Cottin V. The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis. Expert Opin Drug Saf. 2017, 16:857-65. 10.1080\/14740338.2017.1338268","journal-title":"Expert Opin Drug Saf"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0057-2017","article-title":"Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis","volume":"26","author":"Lancaster LH","year":"2017","unstructured":"Lancaster LH, de Andrade JA, Zibrak JD, et al.. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. Eur Respir Rev. 2017, 26:170057. 10.1183\/16000617.0057-2017","journal-title":"Eur Respir Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-1298-1","article-title":"Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS\u00ae trials","volume":"21","author":"Kreuter M","year":"2020","unstructured":"Kreuter M, Wuyts WA, Wijsenbeek M, et al.. Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS\u00ae trials. Respir Res. 2020, 21:36. 10.1186\/s12931-020-1298-1","journal-title":"Respir Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-019-1030-4","article-title":"Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis","volume":"20","author":"Richeldi L","year":"2020","unstructured":"Richeldi L, Kolb M, Jouneau S, et al.. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm Med. 2020, 20:3. 10.1186\/s12890-019-1030-4","journal-title":"BMC Pulm Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02593-2017","article-title":"Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis","volume":"52","author":"Flaherty KR","year":"2018","unstructured":"Flaherty KR, Kolb M, Vancheri C, Tang W, Conoscenti CS, Richeldi L. Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2018, 52: 1702593. 10.1183\/13993003.02593-2017","journal-title":"Eur Respir J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/resp.13647","article-title":"Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS\u00ae-ON","volume":"25","author":"Song JW","year":"2020","unstructured":"Song JW, Ogura T, Inoue Y, et al.. Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS\u00ae-ON. Respirology. 2020, 25:410-6. 10.1111\/resp.13647","journal-title":"Respirology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-01458-1","article-title":"Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study","volume":"21","author":"Moor CC","year":"2020","unstructured":"Moor CC, Mostard RL, Grutters JC, et al.. Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study. Respir Res. 2020, 21:196. 10.1186\/s12931-020-01458-1","journal-title":"Respir Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2018.11.012","article-title":"Lung function outcomes in the INPULSIS\u00ae trials of nintedanib in idiopathic pulmonary fibrosis","volume":"146","author":"Brown KK","year":"2019","unstructured":"Brown KK, Flaherty KR, Cottin V, et al.. Lung function outcomes in the INPULSIS\u00ae trials of nintedanib in idiopathic pulmonary fibrosis. Respir Med. 2019, 146:42-8. 10.1016\/j.rmed.2018.11.012","journal-title":"Respir Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.04.016","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment","volume":"153","author":"Nathan SD","year":"2019","unstructured":"Nathan SD, Costabel U, Albera C, et al.. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. Respir Med. 2019, 153:44-51. 10.1016\/j.rmed.2019.04.016","journal-title":"Respir Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.11.008","article-title":"Efficacy of pirfenidone in the context of multiple disease progression events in patients with idiopathic pulmonary fibrosis","volume":"155","author":"Nathan SD","year":"2019","unstructured":"Nathan SD, Costabel U, Glaspole I, et al.. Efficacy of pirfenidone in the context of multiple disease progression events in patients with idiopathic pulmonary fibrosis. Chest. 2019, 155:712-9. 10.1016\/j.chest.2018.11.008","journal-title":"Chest"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00399-2019","article-title":"Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis","volume":"54","author":"Glassberg MK","year":"2019","unstructured":"Glassberg MK, Wijsenbeek MS, Gilberg F, Petzinger U, Kirchgaessler KU, Albera C. Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2019, 54:1900399. 10.1183\/13993003.00399-2019","journal-title":"Eur Respir J"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201810-720RL","article-title":"Pirfenidone treatment in individuals with idiopathic pulmonary fibrosis: impact of timing of treatment initiation","volume":"16","author":"Maher TM","year":"2019","unstructured":"Maher TM, Lancaster LH, Jouneau S, et al.. Pirfenidone treatment in individuals with idiopathic pulmonary fibrosis: impact of timing of treatment initiation. Ann Am Thorac Soc. 2019, 16:927-30. 10.1513\/AnnalsATS.201810-720RL","journal-title":"Ann Am Thorac Soc"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202007-901OC","article-title":"Adoption of the antifibrotic medications pirfenidone and nintedanib for patients with idiopathic pulmonary fibrosis","volume":"18","author":"Dempsey TM","year":"2021","unstructured":"Dempsey TM, Payne S, Sangaralingham L, Yao X, Shah ND, Limper AH. Adoption of the antifibrotic medications pirfenidone and nintedanib for patients with idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2021, 18:1121-8. 10.1513\/AnnalsATS.202007-901OC","journal-title":"Ann Am Thorac Soc"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1021\/jm900431g","article-title":"Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)","volume":"52","author":"Roth GJ","year":"2009","unstructured":"Roth GJ, Heckel A, Colbatzky F, et al.. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem. 2009, 52:4466-80. 10.1021\/jm900431g","journal-title":"J Med Chem"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg F","year":"2008","unstructured":"Hilberg F, Roth GJ, Krssak M, et al.. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008, 68:4774-82. 10.1158\/0008-5472.CAN-07-6307","journal-title":"Cancer Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00001111","article-title":"Antifibrotic activities of pirfenidone in animal models","volume":"20","author":"Schaefer CJ","year":"2011","unstructured":"Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev. 2011, 20:85-97. 10.1183\/09059180.00001111","journal-title":"Eur Respir Rev"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2008.06.046","article-title":"Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis","volume":"590","author":"Oku H","year":"2008","unstructured":"Oku H, Shimizu T, Kawabata T, et al.. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol. 2008, 590:400-8. 10.1016\/j.ejphar.2008.06.046","journal-title":"Eur J Pharmacol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-1161-4","article-title":"Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat","volume":"20","author":"Maher TM","year":"2019","unstructured":"Maher TM, Strek ME. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respir Res. 2019, 20:205. 10.1186\/s12931-019-1161-4","journal-title":"Respir Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.105803","article-title":"Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment","volume":"159","author":"Cerri S","year":"2019","unstructured":"Cerri S, Monari M, Guerrieri A, et al.. Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment. Respir Med. 2019, 159:105803. 10.1016\/j.rmed.2019.105803","journal-title":"Respir Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1159\/000490667","article-title":"Identifying barriers to idiopathic pulmonary fibrosis treatment: a survey of patient and physician views","volume":"96","author":"Maher TM","year":"2018","unstructured":"Maher TM, Swigris JJ, Kreuter M, et al.. Identifying barriers to idiopathic pulmonary fibrosis treatment: a survey of patient and physician views. Respiration. 2018, 96:514-24. 10.1159\/000490667","journal-title":"Respiration"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/181524-a-comparison-of-the-effectiveness-of-nintedanib-and-pirfenidone-in-treating-idiopathic-pulmonary-fibrosis-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T21:56:13Z","timestamp":1708034173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/181524-a-comparison-of-the-effectiveness-of-nintedanib-and-pirfenidone-in-treating-idiopathic-pulmonary-fibrosis-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.54268","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,15]]}}}